Cardiovascular Research Advance Access first published online on February 13, 2009
This version [Corrected Proof] published online on March 4, 2009
Cardiovascular Research, doi:10.1093/cvr/cvp062
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cardioprotective growth factors
The Hatter Cardiovascular Institute, University College London Hospital and Medical School, 67 Chenies Mews, London WC1E 6HX, UK
* Corresponding author. Tel: +44 207 380 9888; fax: +44 207 380 9505. E-mail address: hatter-institute{at}ucl.ac.uk
Many of the originally identified cardiovascular growth factors have been demonstrated to exert a diverse variety of actions within the cardiovascular system, the majority of which are unrelated to their initially proposed mechanism of action. Interestingly, several of these growth factors have been demonstrated to protect the cardiomyocyte from the detrimental effects of acute ischaemia–reperfusion injury, through the activation of a variety of cell-surface receptors and the subsequent recruitment of a number of intracellular signal transduction pathways, which include components of the reperfusion injury salvage kinase pathway. This article will review several of these cardioprotective growth factors with respect to their ability to confer direct myocardial protection, focusing on the underlying signalling pathways involved and their potential for clinical application.
KEYWORDS Cardioprotection; Ischaemia; Reperfusion; Growth factors
Time for primary review: 23 days
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
H. M. Piper and D. Garcia-Dorado Cardiac protection takes off Cardiovasc Res, July 15, 2009; 83(2): 163 - 164. [Full Text] [PDF] |
||||
